Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1/2a placebo-controlled inhaled AUGM-101 study in healthy volunteers and hospitalized patients with mild to moderate COVID-19
MOH_2021-04-08_009760Phase 2Completed
- Sponsor
- Augmenti Nano
- Start
- Apr 2021
- Countries
- 1
01
Overview
Phase 2, randomised trial of AUGM-101 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Augmenti Nano. Primary endpoints: Safety and tolerability in healthy volunteers, Safety and tolerability in patients with COVID-19 and 1 more. Started Apr 2021; status: completed.
02
Drugs
AUGM-101
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2021-04-08_009760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-08_009760.